Refine your search
3,825 results found
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | USA | 1 Jun 2023
IPR and PGR Statistics for Final Written Decisions Issued in April 2023
In April, a relatively difficult month for patent owners, the PTAB cancelled 524 (86.33%) instituted claims across 43 IPR and PGR Final Written…
Wilmer Cutler Pickering Hale and Dorr LLP | USA | 30 May 2023
Federal Circuit Patent Watch: Federal Circuit rejects invitation to abandon abuse-of-discretion standard of review in attorneys’ fees appeal
Clevenger, J. The Court affirmed a district court decision denying a Defendant’s motion for attorneys’ fees under 35 U.S.C. § 285. Two days after…
Global Arbitration Review | Asia-Pacific | 26 May 2023
The rise of arbitration in the Asia-Pacific region
Arbitral hubs and institutions in Asia have reached new heights in terms of their growth and popularity, achieving stellar global rankings and an…
Reed Smith LLP | USA | 26 May 2023
NPP, DCC, And FDA-Regulated Medical Products
Politics makes strange bedfellows. So does the law. Weird cases also make weird law. The Supreme Court decision in National Pork Producers Council v…
Knobbe Martens | USA | 25 May 2023
Low-Bar for Corroboration
Medtronic filed five IPRs against patents related to catheters, relying on a single prior art reference under pre-AIA 35 U.S.C 102(e). Teleflex…
Kilburn & Strode LLP | European Union, United Kingdom | 24 May 2023
EPO Enlarged Board of Appeal tackles priority - what you need to know ahead of the hearing
It is certainly an exciting time at the EPO - barely a month after the long awaited G2/21 decision, the EPO Enlarged Board of Appeal (EBA) is getting…
Ropes & Gray LLP | USA | 24 May 2023
Will the Third Time Be the Charm for ITC Reform? Bipartisan Bill Reintroduced in Effort to Restrict NPE Activity at the ITC
On May 18, 2023, Representatives David Schweikert (R-AZ) and Don Beyer (D-VA) co-sponsored and reintroduced the “Advancing America’s Interests Act”…
Reed Smith LLP | USA | 19 May 2023
Mifepristone manufacturer wins first round in West Virginia
The core premise of Bexis’ article is very simple: Once the FDA has said “yes” and approved a particular drug for a particular indication (“intended…
McDermott Will & Emery | USA | 18 May 2023
Pending Appeal Does Not Divest Board of Statutory Authority to Institute IPRs
In a case involving sua sponte review, the Director of the US Patent & Trademark Office (PTO) vacated an inter partes review (IPR) decision denying…
Hogan Lovells | European Union, USA | 17 May 2023
Technology policy’s next big challenge: Divergent approaches to regulating AI
The rapid growth of AI and its ramifications for nearly all aspects of society and the economy is placing increasing pressure on the U.S. and…
